Abstract
Purpose
Alimentary tract (AT) mucositis is a serious problem complicating cancer treatment, however, its pathobiology remains incompletely understood. Nuclear factor-κB (NF-κB) and pro-inflammatory cytokines are considered to have important roles in its development. This has been previously demonstrated in different sites of the AT following administration of irinotecan in an animal model using the Dark Agouti rat. The aim of the present study was to determine whether the changes that occur in the AT are affected by the type of mucotoxic drug.
Methods
Female DA rats were given a single dose of either methotrexate (1.5 mg/kg intramuscularly) or 5-fluorouracil (150 mg/kg intraperitoneally). Rats were killed at 30, 60, 90 min, 2, 6, 12, 24, 48 and 72 h. Control rats received no treatment. Samples of oral mucosa, jejunum and colon were collected. Haematoxylin and eosin stained sections were examined with respect to histological evidence of damage and standard immunohistochemical techniques were used to demonstrate tissue expression of NF-κB, TNF, IL-1β and IL-6.
Results
Both MTX and 5-FU administration caused histological evidence of tissue damage in the AT as well as changes in tissue expression of NF-κB and specific pro-inflammatory cytokines. This study, however, demonstrated that there were differences in the timing of histological changes as well as the timing and intensity of pro-inflammatory cytokine tissue expression caused by the different drugs.
Conclusions
The results from this study suggest that there are differences in the mucositis pathobiology caused by different drugs. This may have important ramifications for the management of mucositis particularly with respect to the development of treatment regimens for mucositis. Further investigations are required to determine the exact pathways that lead to damage caused by the different drugs.
Similar content being viewed by others
References
Anthony L, Bowen J, Garden A et al (2006) New thoughts on the pathobiology of regimen-related mucosal injury. Support Care Cancer 14:516–518
Aota K, Azuma M, Yamashita T et al (2000) 5-Fluorouracil induces apoptosis through the suppression of NF-[kappa]B activity in human salivary gland cancer cells. Biochem Biophys Res Commun 273:1168–1174
Azuma M, Yamashita T, Aota K et al (2001) 5-Fluorouracil suppression of NF-[kappa]B is mediated by the inhibition of I[kappa]B kinase activity in human salivary gland cancer cells. Biochem Biophys Res Commun 282:292–296
Bowen JM, Gibson RJ, Keefe DM et al (2005) Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology 37:56–62
Carneiro-Filho BA, Lima IP, Araujo DH et al (2004) Intestinal barrier function and secretion in methotrexate-induced rat intestinal mucositis. Dig Dis Sci 49:65–72
Carneiro-Filho BA, Oria RB, Wood Rea K et al (2004) Alanyl-glutamine hastens morphologic recovery from 5-fluorouracil-induced mucositis in mice. Nutrition 20:934–941
Cool JC, Dyer JL, Xian CJ et al (2005) Pre-treatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats. Growth Hormone IGF Res 15:72–82
de Koning BA, Sluis M, Lindenbergh-Kortleve DJ et al (2007) Methotrexate-induced mucositis in mucin 2-deficient mice. J Cell Physiol 210:144–152
Elting LS, Cooksley C, Chambers MS et al (2003) The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98:1531–1539
Gibson RJ, Bowen JM, Cummins AG et al (2005) Relationship between dose of methotrexate, apoptosis, p53/p21 expression and intestinal crypt proliferation in the rat. Clin Exp Med 4:188–195
Gibson RJ, Keefe DM, Thompson FM et al (2002) Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 47:2751–2757
Jones J, Avritscher E, Cooksley C et al (2006) Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer V14:505–515
Keefe D, Schubert M, Elting L et al (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831
Keefe DM (2007) Intestinal mucositis: mechanisms and management. Curr Opin Oncol 19:323–327
Krajewska M, Wang HG, Krajewski S et al (1997) Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. Cancer Res 57:1605–1613
Krajewska M, Zapata JM, Meinhold-Heerlein I et al (2002) Expression of Bcl-2 family member Bid in normal and malignant tissues. Neoplasia 4:129–140
Krajewski S, Krajewska M, Reed JC (1996) Immunohistochemical analysis of in vivo patterns of Bak expression, a proapoptotic member of the Bcl-2 protein family. Cancer Res 56:2849–2855
Kremer JM (2004) Toward a better understanding of methotrexate. Arthritis Rheum 50:1370–1382
Leitão RFC, Ribeiro RA, Bellaguarda EAL et al (2008) Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster. Cancer Chemother Pharmacol 61:215–222
Logan RM, Gibson RJ, Bowen JM et al (2008) Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol (in press)
Logan RM, Stringer AM, Bowen JM et al (2007) The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 33:448–460
Majumdar S, Aggarwal BB (2001) Methotrexate suppresses NF-{kappa}B activation through inhibition of I{kappa}B{alpha} phosphorylation and degradation. J Immunol 167:2911–2920
Papadeas E, Naxakis S, Riga M et al (2007) Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: a randomized controlled study. Eur J Oncol Nurs 11:60–65
Pritchard DM, Jackman A, Potten CS et al (1998) Chemically-induced apoptosis: p21 and p53 as determinants of enterotoxin activity. Toxicol Lett 102–103:19–27
Scully C, Epstein J, Sonis S (2003) Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: Part 1, pathogenesis and prophylaxis of mucositis. Head Neck 25:1057–1070
Sonis ST (1998) Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34:39–43
Sonis ST (2002) The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with antineoplastic therapy. Crit Rev Oral Biol Med 13:380–390
Sonis ST (2004) A biological approach to mucositis. J Support Oncol 2:21–36
Sonis ST, Elting LS, Keefe D et al (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100:1995–2025
Taupin D, Podolsky DK (2003) Trefoil factors: Initiators of mucosal healing. Nat Rev Mol Cell Biol 4:721–732
Xu Y, Villalona-Calero MA (2002) Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 13:1841–1851
Yeoh ASJ, Bowen JM, Gibson RJ et al (2005) Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys 63:1295–1303
Acknowledgments
This project was supported by a research grant awarded by the Royal Adelaide Hospital Research Committee and the Australian Dental Research Foundation Incorporated. Dr. Rachel Gibson was supported by a Cancer Council South Australia Research Fellowship; Dr. Joanne Bowen and Ms. Andrea Stringer by a Dawes Research Scholarship. Assistance with the statistical analysis for this study was provided by Mr. Thomas Sullivan from the Department of Public Health, The University of Adelaide. The authors also acknowledge Ms Marjorie Quinn, Oral Pathology, School of Dentistry, The University of Adelaide for her assistance in cutting sections.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Logan, R.M., Stringer, A.M., Bowen, J.M. et al. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?. Cancer Chemother Pharmacol 63, 239–251 (2009). https://doi.org/10.1007/s00280-008-0732-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-008-0732-8